Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (ZBH) is a global innovator in musculoskeletal healthcare, delivering advanced orthopedic solutions for nearly a century. This news hub provides investors and medical professionals with timely updates on product developments, regulatory milestones, and strategic initiatives shaping the future of surgical care.
Track critical updates including quarterly earnings, FDA clearances for robotic surgery systems, and partnerships advancing AI-driven orthopedic solutions. Our curated feed consolidates press releases about joint reconstruction technologies, trauma care innovations, and global market expansions to inform your analysis of this medtech leader.
Discover how Zimmer Biomet’s integration of digital surgery platforms with traditional orthopedic expertise continues to redefine patient outcomes. Bookmark this page for direct access to verified updates about ZBH’s clinical advancements, without promotional commentary or speculative content.
Zimmer Biomet Holdings, Inc. published its 2023 Sustainability Report highlighting progress in environmental goals, employee engagement, health equity, and quality management. The report showcases the company's commitment to sustainability, including achieving high employee engagement levels, reducing carbon emissions, expanding Zero Waste to Landfill initiative, and maintaining product quality programs. Zimmer Biomet aims to be a leader in responsible business practices and has a roadmap to reach Net-Zero greenhouse gas emissions by 2050.
Zimmer Biomet Holdings, Inc. reported first quarter net sales of $1.889 billion, with a 3.2% increase over the prior year. Diluted earnings per share were $0.84, adjusted diluted earnings per share were $1.94. Recent highlights include FDA clearances for innovative products and partnerships with pickleball organizations. The company reaffirmed its full-year 2024 financial guidance.